Rheumatoid Arthritis (RA) is one of the most frequent and important types of arthritis, as it is a chronic and aggressive disease that causes joint damage, pain and disability. There is no cure, however there are several lines of treatment aimed at symptoms and preventing joint damage and disability. According to the World Health Organization (WHO), RA is one of the leading causes of absenteeism and premature retirement in the world. It affects between 1 and 1.5% of the world population. The main purpose of this review is to capture the generalities of the biological drugs used in the treatment of RA, what they are, how they are used, types, adverse effects and recommendations to avoid said effects or treat them. The research model is a bibliographic documentary type review. The review shows that biological drugs are used as a second line of action, in the treatment of patients with RA refractory to synthetic disease-modifying antirheumatic drugs (DMARDs). There are several types of these drugs that vary from one country to another, as well as the legislation that regulates them and their costs. Likewise, its effectiveness is associated with other DMARDs, especially when administered with methotrexate. The combination of DMARDs presents better results than its single administration. These biologics effectively improve clinical, functional, and radiographic outcomes, and delay radiographic progression in most cases. Lastly, it is essential to monitor these patients during DMARD treatment since the presence of some side effects is possible.